PC
IART icon

Pavadi Capital’s Integra LifeSciences IART Stock Holding History

Pavadi Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-99,999
Closed -$3.82M – 16
2023
Q3 		$3.82M Sell
99,999
-11,956
-11% -$503K 4.97% 14
2023
Q2 		$4.6M Sell
111,955
-16,803
-13% -$809K 5.37% 13
2023
Q1 		$7.39M Buy
128,758
+20,091
+18% +$1.13M 8.07% 1
2022
Q4 		$6.09M Buy
+108,667
New +$5.53M 5.74% 6

Other funds holding IART

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pavadi Capital's IART Position: Q4 2023 in Review

Pavadi Capital sold out of Integra LifeSciences (IART) in Q4 2023, closing a stake of 99,999 shares — an estimated $3.82M sold.

Pavadi Capital first reported a position in IART in Q4 2022 and held it in 4 quarters. The position peaked at $7.39M in Q1 2023. 284 funds tracked by Wall St. Rank hold IART as of Q4 2023.

  • Pavadi Capital reported no remaining Integra LifeSciences position as of Q4 2023 after selling out during the quarter.
  • Pavadi Capital sold 99,999 Integra LifeSciences shares in Q4 2023, an estimated $3.82M.
  • Pavadi Capital first reported a position in Integra LifeSciences in Q4 2022 and held it in 4 quarters.
  • Pavadi Capital's Integra LifeSciences position peaked at $7.39M in Q1 2023.
  • 284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2023.

Based on Pavadi Capital's 13F filing for Q4 2023, filed 14 Feb 2024.